KRAS and nervous system disorder: Authors reported, for instance, on BRAF mutations as being associated with neurologic disease (183 of 273 patients, 67%, p < 0.001), KRAS and NRAS with cutaneous and pleural involvement (583 and 44% of patients, respectively), and MAP2K1 with peritoneal and retroperitoneal lesions (4 of 11 patients, 36.4%, p = 0.01); PIK3CA was not associated with specific organ involvement.